Manufacture of Bulk Chemicals & Bulk Pharmaceutical Ingredients For Preclinical &

开发治疗计划(DTP)，癌症治疗和诊断部(DCTD)，国家癌症研究所(NCI)进行具有抗癌活性的药物的开发。这些药物来自NCI实验治疗(NEXT)计划。此外，开发项目可能来自临床显像剂和增强剂开发(DCide)计划、化学预防部门(DCP)计划、1型糖尿病RAID计划(T1D-RAID)和NIH快速干预开发(NIH-RAID)计划。NCI内部计划也是开发化合物的来源。 承包商提供服务、人员、设备和设施，以制造多克和/或千克规模的各种选定的散装化合物。制备的原料药将用于各种癌症适应症的临床前毒性研究、配方前和临床试验。承包商提交的技术报告可用于支持向美国食品和药物管理局(FDA)提交的调查性新药申请(IND)。合同已被选为实现NCI抗癌药物开发目标的工具。

The Developmental Therapeutic Program (DTP), Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI) conducts development of agents with anticancer activity. The agents arise from the NCI Experimental Therapeutics (NExT) program. In addition, development projects could arise from Development of Clinical Imaging Agents and Enhancers (DCIDE) program, Division of Chemoprevention (DCP) program, Type-1 Diabetes RAID program (T1D-RAID), and NIH Rapid Access to Intervention Development (NIH-RAID) program. The NCI intramural program has also been a source of compounds for development. The contractor provides services, personnel, equipment and facilities to manufacture a variety of the selected bulk compounds in multi-gram and/or kilogram scale. The prepared bulk material is to be used for preclinical toxicity studies, preformulation and clinical trials for the various cancer indications. Technical reports submitted by the contractor may be used to support Investigational New Drug Applications (IND) submitted to the US Food and Drug Administration (FDA). Contracts have been chosen as instruments to accomplish the goals of cancer drug development at the NCI.